title: Late effects in survivors of teenage and young adult cancer: does age matter?
abstract: BACKGROUND
  Late effects (LEs) after cancer treatment are increasing. After childhood cancer, substantial risks include physical, psychological and social LE and vary with age. Teenagers and young adults (TYA) present with particular cancers; their risk of LE may relate to cancer site, treatment or their age itself. The LEs after TYA-onset cancers are described in relation to age at diagnosis of primary tumour.
  
  
  METHODS
  Data were extracted from Medline English language articles, 1999-2009. Keywords were late effect/s, late toxicity and survivor and the frequent TYA cancer sites. Only those articles that reported the relation between LEs risks with age at diagnosis were included.
  
  
  RESULTS
  The majority of known LEs are described after TYA cancer. No study primarily aimed to relate TYA age to LEs. Many studies did not report LE by age. TYA-specific risks are seen in cardiac toxicity, second malignancies, pulmonary complications and psychosocial difficulties when compared with older or younger cancer survivors.
  
  
  CONCLUSIONS
  TYA age brings specific LE risks after cancer. Prospective population-based collection of LE data after TYA cancer will inform the development of appropriate services to effectively manage LE.
authors.affiliation: Cancer Medicine, St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds; Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.
authors.forename: E
authors.initials: E
authors.lastname: Woodward
authors.affiliation: Cancer Medicine, St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds; Department of Paediatric Oncology, Queensland Children's Cancer Centre, Brisbane, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Jessop
authors.affiliation: Department of Paediatric Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: A
authors.initials: A
authors.lastname: Glaser
authors.affiliation: Cancer Medicine, St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds; Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK. Electronic address: d.p.stark@leeds.ac.uk.
authors.forename: D
authors.initials: D
authors.lastname: Stark
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000970:Antineoplastic Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007246:Infertility / Q000209:etiology; D007674:Kidney Diseases / Q000453:epidemiology / Q000209:etiology; D008171:Lung Diseases / Q000453:epidemiology / Q000209:etiology; D008659:Metabolic Diseases / Q000453:epidemiology / Q000209:etiology; D009369:Neoplasms / Q000523:psychology / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D017741:Survivors / Q000523:psychology; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents